Loading
A phase 2/3 trial of Prednisone, Vinblastine, Mercaptopurine, Methotrexate, Cytarabine, Cladribine and Human normal immunoglobulin in Langerhans cell histiocytosis, run by North American Consortium for Histiocytosis, active and no longer recruiting.
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis is a phase 2/3 interventional study registered as NCT02205762 by North American Consortium for Histiocytosis, with 1400 participants planned, started 2016-11-02 and due to reach its primary completion in 2026-07. Interventions recorded: Prednisone, Vinblastine, mercaptopurine, INDOMETHACIN, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, hematopoietic stem cell transplantation (RIC-HSCT), Intravenous immunoglobulin. Conditions recorded: Langerhans Cell Histiocytosis.
Linked to the drug Human normal immunoglobulin because the registry names it among its interventions and Langerhans cell histiocytosis among its conditions. Registry record only: no result has been read by an editor.
Shares Cladribine, Cytarabine, Prednisone and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate, Prednisone and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate, Prednisone and the tag pipeline.
Shares Mercaptopurine, Vinblastine, Cytarabine, Methotrexate and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate and the tag pipeline.
Shares Mercaptopurine, Cytarabine, Methotrexate, Prednisone and the tag pipeline.
Shares Cytarabine, Methotrexate, Prednisone and the tag pipeline.
Shares Cytarabine, Methotrexate, Prednisone and the tag pipeline.